| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
08-25-2018, 02:57 AM
|
#2 | ||
|
|||
|
Senior Member
|
I can only find the Abstract describing this research:
https://www.iaprd-world-congress.com..._Abstracts.pdf The conclusions: "a single time oral administration of Nilotinib may increase brain dopamine levels and metabolism. These results suggest Nilotinib, in a dose dependent manner, may have a symptomatic effect through modulation of brain dopamine levels. Additionally, the significant reduction of oligomeric alpha-synuclein, which is expected to increase in the CSF of PD patients as the disease progresses, suggests that Nilotinib may reduce misfolded alpha-synuclein accumulation and have a longterm disease modifying effect. Importantly, the dose response of oligomeric alpha-synuclein and HVA changes to nilotinib suggests that the dose administered may depend on the stage of disease to potentially halt PD progression." John
__________________
Born 1955. Diagnosed PD 2005. Meds 2010-Nov 2016: Stalevo(75 mg) x 4, ropinirole xl 16 mg, rasagiline 1 mg Current meds: Stalevo(75 mg) x 5, ropinirole xl 8 mg, rasagiline 1 mg |
||
|
 Reply With Quote
|
| "Thanks for this!" says: | RooJr (08-25-2018) |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| Gocovri Improves Dyskinesia in Parkinson’s Patients Over Long Term, Phase 3 Trial | Parkinson's Disease | |||
| MRI-Focused Ultrasound Undergoing Phase 3 Clinical Trial for Parkinson’s Treatment | Parkinson's Disease | |||
| Phase 2 Trial Testing Leukemia Treatment, Nilotinib | Parkinson's Disease | |||
| Voyager’s Gene Therapy to Enter Phase 2/3 Trial Program for Adv Parkinson’s Dise | Parkinson's Disease | |||
| Recruitment has begun for the Georgetown University "PD Nilotinib" phase 2 trial | Parkinson's Disease | |||
Threaded Mode